PDCD1 and neoplasm: Furthermore, separate research examined the immune profile and transcriptomics of 158 tumor samples obtained from advanced melanoma patients who received either anti-PD-1 monotherapy (n = 63) or a combination of anti-PD-1 and anti-CTLA-4 (n = 57) [101,102].